Lineage Cell Therapeutics
Logotype for Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics (LCTX) investor relations material

Lineage Cell Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Lineage Cell Therapeutics Inc
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • Acquired NeuroAirmid on November 12, adding worldwide rights to HUNT1, a Phase 1b/2a Huntington’s disease cell therapy; six participants had been dosed in REGEN4HD, with no serious adverse events reported.

  • Advanced OpRegen, OPC1, COR1, ReSonance and manufacturing-platform programs alongside the HUNT1 acquisition.

Financial highlights

  • Q3 2026 revenue was $1.434M versus $3.681M a year earlier, down 61%; lower Roche collaboration revenue and WDI services drove the decline.

  • Q3 operating expenses were $8.748M versus $7.467M; operating loss widened to $7.314M from $3.786M.

  • Q3 net income attributable to common shareholders was $4.232M versus a $29.781M loss; the result included a non-cash $11.944M warrant revaluation gain.

  • Nine-month revenue was $4.228M versus $7.948M; operating loss was $23.830M versus $30.071M, and net income was $0.902M versus a $64.384M loss.

Outlook and guidance

  • Cash, cash equivalents and marketable securities totaled $45.2M at September 30, 2026, and were expected to fund planned operations into Q2 2028.

  • Initial COR1 preclinical functional-model data were expected in Q1 2027; a ReSonance development-planning meeting with Denmark’s medicines agency was being prepared for Q4 2026.

  • HUNT1 clinical costs were estimated at less than $2M annually, with a CIRM award of up to $12M to UC Irvine and co-funding obligations of up to $3.1M.

  • Operating losses were expected to continue for several years, with additional capital needed as development and regulatory work advances.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Lineage Cell Therapeutics earnings date

Logotype for Lineage Cell Therapeutics Inc
Q4 20264 Mar, 2027
Lineage Cell Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Lineage Cell Therapeutics earnings date

Logotype for Lineage Cell Therapeutics Inc
Q4 20264 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Lineage Cell Therapeutics Inc is a biotechnology company developing cell-based therapies for degenerative diseases. The company focuses on regenerative medicine approaches for ophthalmology, neurology, and oncology, using proprietary cell manufacturing platforms. The company is headquartered in Carlsbad, California, and its shares are listed on the NYSE American.